Press releases

Oxford Biomedica notes that Axovant has announced the dosing of the first patient in the second cohort of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD

-       Under terms of the agreement with Axovant signed in June 2018, this has triggered a $15 million milestone to Oxford Biomedica

Oxford, UK – 30 April 2019: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, notes that Axovant Gene Therapies Ltd. (NASDAQ: AXGT) has announced the dosing of the first patient of the second cohort in the SUNRISE-PD Phase 2 trial of AXO-Lenti-PD in Parkinson’s disease patients. To date, the patient has experienced no complications related to the surgery or to administration of the vector and has been discharged home as planned with no serious adverse events observed. Up to six patients will be dosed in this second cohort, at a dose of 1.4 x 107 TU,  which is approximately three-fold higher than the dose evaluated in the first cohort. The primary outcome measure in this second cohort is safety and tolerability and a key efficacy measure will be UPDRS Part III (motor) OFF score. Axovant expects initial data from this cohort to be available in the fourth quarter of 2019. 

To view the full announcement from Axovant, please follow this link.

-Ends-

Enquiries:
Oxford Biomedica plc
John Dawson, Chief Executive Officer
T: +44 (0)1865 783 000

Stuart Paynter, Chief Financial Officer
T: +44 (0)1865 783 000

Catherine Isted, Head of Corporate Development & IR
T: +44 (0)1865 954 161 / E: ir@oxb.com

Sarah MacLeod, Head of Communications
T: +44 (0)7747 602 739 / E: media@oxb.com

Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal
T: +44 (0)20 3709 5700

About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 430 people. For more information, visit www.oxb.com

About Axovant Gene Therapies
Axovant, part of the Roivant family of companies, is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurological and neuromuscular diseases. The company’s current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis (including Tay-Sachs disease and Sandhoff disease), Parkinson’s disease, oculopharyngeal muscular dystrophy (OPMD), amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. Axovant is focused on accelerating product candidates into and through clinical trials with a team of experts in gene therapy development and through external partnerships with leading gene therapy organizations. For more information, visit www.axovant.com.

About Roivant
Roivant Sciences aims to improve health by rapidly delivering innovative medicines and technologies to patients. It does this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology to drive greater efficiency in R&D and commercialization. For more information, please visit www.roivant.com.